Faron Pharmaceuticals Oy Share Discussion Threads

[pilkersa] 21/2/2019 08:01

I am in. Let's see where it goes....

[daffodil4] 13/2/2019 14:32

I think that Clevegen will be a massive success..
but it is only in phase 2, so probably 2 years
from approval...what is holding back the share price IMO
is the question of funding to see Trauamkine
development completed...We have 3/4 months
cash in reserve, and it was stated in the
Proactive interview early Novemeber that
we 'needed' a Partner to complete the development
of Traumakine, so I think Faron need to confirm
that funds going forward have been secured...
which also begs the question..what will such a deal
mean for existing holders..if we have to raise without
having any approved drugs...(but great potential)..
That is what is holding back the share price IMHO!

[pre] 13/2/2019 09:14

very clever and excellent news for holders....this is great news for cancer treatment patients and looks like the significance of this has gone unnoticed...were just trading under £9 last year...

[fillipe] 13/2/2019 09:06

Being very well received, 0900hrs onwards.

f

[safman] 13/2/2019 09:05

Dr Markku Jalkanen, Chief Executive Officer of Faron, said: "We are very pleased about these published results by Faron's scientific network. We believe that the next significant step in cancer treatment is based on biomarker-guided use of selective immunotherapeutic drugs, alone or in combination. Faron's investigational immunotherapeutic, Clevegen, provides a unique new feature to these options by removing immune suppression from the tumour environment and potentially increasing efficacy of immunotherapy checkpoint molecules. We hope to see supportive biomarker changes in our MATINS trial patients during the first half of 2019 while we advance development of Clevegen as a novel therapy for patients with currently untreatable solid cancers."

Following Faron's participation in the funding of this research work, the Company has filed a new patent application for the combined use of Clevegen and immunotherapy checkpoint inhibitors to treat cancer.

new patent pending now for farn...

saffy..

[safman] 13/2/2019 09:02

rns out this morning...

saffy..

[big brother8] 12/2/2019 18:04

Yes it got a pulse, to suck punters. This is normal when a share is flatline.

[big brother8] 12/2/2019 18:01

A minus -70% is cumming.

I think Ant and his army been shorting for a while. He's shouting 25p on the darknet. If you know his twitter handle, you will see it. You know what he did to MATD AND Angs.

Going against Ant will be back for your health.

I see rampers going here and trying to bottom feed.


Shares do not collapse by 93% if it's a good shares




DRIP DRIP DRIP

BANNNNNNNNNNNNNNNNNG 25P

[pre] 07/2/2019 13:08

50,000 was a delayed buy...look at the time it was executed...11.55...they got them at a great price and paid a premium for them...

[daffodil4] 07/2/2019 13:04

Herb

A rise on no news and a 50,0000 sell...
I never trust a rise on no RNS...Look
what happened at AMP today!!

[herb clark] 07/2/2019 13:04

Think 50k was a sell

[pre] 07/2/2019 13:03

someone snapped up another 50,000..some other big buyers moving in...plenty of news due....

[herb clark] 07/2/2019 12:56

Why the rise?

[daffodil4] 03/2/2019 11:57

We have pretty much been told that they expect the
Japan Trial to mirror the european trial...they
have delayed issuing the results, from Q3 2018
to Q1 2019..The big issue is funding they
only have a few months cash left, so they
need to address it before Nomad will have a duty
to act..Traumakine trial needs to be repeated
so we are sometime away from approval IMO.

[thecashmoney] 02/2/2019 13:06

Reading between the lines , the Japanese results could come in positive. Looks like have found a irregularities in the US trials this will be interesting. Building position here as these was £9 on anticipation.

[pre] 31/1/2019 11:14

just done some research...they were trading over £8 just under a year ago, and this move up could be just the signal of positive news in pipeline, extract from rns:

Dr Markku Jalkanen, CEO of Faron, said: 'We believe these results confirm that the drug product used in the INTEREST study was robust and effective. While analysis continues, we believe the mixed results seen were due to a higher than anticipated placebo response due to high pneumonia portion, interference of corticosteroids on IFN-beta bioactivity and, as recently announced, the impact of a subgroup of patients' single nucleotide polymorphism C/T mutation in their interferon alpha and beta receptor gene.'

[pre] 31/1/2019 08:40

fallen from around +£8....Japan results leak (?) could see this multiples of current share price if positive....

[bioking] 30/1/2019 15:15

21% and running wow love it

[bioking] 30/1/2019 15:01

takeover by japan partner maruishi is also possible because of its super low valuation of 17 million

[bioking] 30/1/2019 15:00

RALLYYYYYYYYYYYYYYYYYYYy up 18% so far

[bioking] 30/1/2019 14:43

running higher maybe someone knows ahead about the japanese phase 3 results . Whatever it smells like good news is imminent .lets hope for a 100% jump then i will dump